257.78
price down icon0.61%   -1.58
after-market アフターアワーズ: 257.65 -0.13 -0.05%
loading
前日終値:
$259.36
開ける:
$257.5
24時間の取引高:
6.15M
Relative Volume:
0.74
時価総額:
$621.22B
収益:
$97.93B
当期純損益:
$21.04B
株価収益率:
29.88
EPS:
8.6278
ネットキャッシュフロー:
$17.80B
1週間 パフォーマンス:
+1.52%
1か月 パフォーマンス:
-4.34%
6か月 パフォーマンス:
+13.98%
1年 パフォーマンス:
+34.34%
1日の値動き範囲:
Value
$254.56
$257.80
1週間の範囲:
Value
$251.50
$262.44
52週間の値動き範囲:
Value
$184.66
$281.07

Johnson Johnson Stock (JNJ) Company Profile

Name
名前
Johnson Johnson
Name
セクター
Healthcare (1052)
Name
電話
732-524-2455
Name
住所
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Name
職員
140,800
Name
Twitter
@jnjnews
Name
次回の収益日
null
Name
最新のSEC提出書
Name
JNJ's Discussions on Twitter

Compare JNJ vs LLY, ABBV, MRK, NVS

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
JNJ icon
JNJ
Johnson Johnson
257.78 621.22B 97.93B 21.04B 17.80B 8.6278
LLY icon
LLY
Lilly Eli Co
1,270.75 1.13T 72.25B 25.28B 10.37B 27.78
ABBV icon
ABBV
Abbvie Inc
284.80 503.28B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
149.88 369.78B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
153.93 292.58B 54.66B 13.58B 16.05B 7.0171

Johnson Johnson Stock (JNJ) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-02 再開されました UBS Buy
2026-05-13 アップグレード Leerink Partners Market Perform → Outperform
2026-04-08 再開されました TD Cowen Buy
2026-01-28 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-11-13 開始されました Scotiabank Sector Outperform
2025-10-20 アップグレード Daiwa Securities Neutral → Outperform
2025-10-03 アップグレード Wells Fargo Equal Weight → Overweight
2025-09-23 アップグレード Guggenheim Neutral → Buy
2025-07-23 アップグレード Erste Group Hold → Buy
2025-05-13 ダウングレード Leerink Partners Outperform → Market Perform
2024-12-10 再開されました BofA Securities Neutral
2024-11-15 開始されました Wolfe Research Outperform
2024-07-23 ダウングレード Daiwa Securities Outperform → Neutral
2024-05-30 再開されました Goldman Neutral
2024-04-18 アップグレード HSBC Securities Hold → Buy
2023-12-13 ダウングレード Wells Fargo Overweight → Equal Weight
2023-12-01 アップグレード UBS Neutral → Buy
2023-10-05 開始されました RBC Capital Mkts Outperform
2023-09-06 開始されました HSBC Securities Hold
2023-05-30 再開されました Citigroup Buy
2023-03-29 開始されました UBS Neutral
2023-03-01 開始されました Guggenheim Neutral
2022-11-18 開始されました Credit Suisse Neutral
2022-10-18 開始されました Barclays Equal Weight
2022-10-14 繰り返されました BofA Securities Neutral
2022-06-22 開始されました Daiwa Securities Outperform
2022-05-23 再開されました SVB Leerink Outperform
2022-04-06 再開されました Morgan Stanley Equal-Weight
2022-03-16 ダウングレード Bernstein Outperform → Mkt Perform
2022-03-02 再開されました BofA Securities Neutral
2021-12-17 開始されました Goldman Neutral
2021-12-15 繰り返されました Citigroup Buy
2021-09-07 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-05-28 再開されました Morgan Stanley Overweight
2020-04-28 ダウングレード UBS Buy → Neutral
2020-04-22 アップグレード BofA/Merrill Neutral → Buy
2020-03-05 開始されました Citigroup Buy
2019-12-19 アップグレード Barclays Equal Weight → Overweight
2019-12-17 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-11-20 開始されました Cantor Fitzgerald Overweight
2019-10-16 アップグレード Atlantic Equities Underweight → Neutral
2019-10-11 アップグレード Bernstein Mkt Perform → Outperform
2019-07-12 再開されました Credit Suisse Outperform
2019-05-28 開始されました Goldman Buy
2019-01-23 繰り返されました Barclays Equal Weight
2018-07-12 アップグレード Goldman Sell → Neutral
2018-06-27 開始されました Bernstein Mkt Perform
2018-04-23 繰り返されました Citigroup Neutral
2018-04-18 繰り返されました Stifel Hold
2018-01-24 繰り返されました Stifel Hold
2018-01-12 繰り返されました Wells Fargo Outperform
2018-01-02 ダウングレード JP Morgan Overweight → Neutral
2017-10-18 繰り返されました RBC Capital Mkts Outperform
2017-10-18 繰り返されました Stifel Hold
すべてを表示

Johnson Johnson (JNJ) 最新ニュース

pulisher
01:00 AM

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
10:00 AM

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool

10:00 AM
pulisher
08:00 AM

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now? - Zacks Investment Research

08:00 AM
pulisher
05:20 AM

Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)? - Zacks Investment Research

05:20 AM
pulisher
Oct 20, 2026

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going) - The Motley Fool

Oct 20, 2026
pulisher
Oct 20, 2026

GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research

Oct 20, 2026
pulisher
Oct 20, 2026

CA-JOHNSON-&-JOHNSON - The Facts

Oct 20, 2026
pulisher
Oct 20, 2026

Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half - News-Press NOW

Oct 20, 2026
pulisher
Oct 20, 2026

Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half - Yahoo Finance

Oct 20, 2026
pulisher
Oct 20, 2026

Johnson & Johnson's heart catheter halves treatment time and limits blood-flow blockage - Stock Titan

Oct 20, 2026
pulisher
Oct 20, 2026

Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026 - BioSpace

Oct 20, 2026
pulisher
Oct 20, 2026

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors - GlobeNewswire Inc.

Oct 20, 2026
pulisher
Oct 20, 2026

Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026 - Business Wire

Oct 20, 2026
pulisher
Oct 20, 2026

The £4bn cancer scandal over baby powder - The Telegraph

Oct 20, 2026
pulisher
Oct 19, 2026

2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research

Oct 19, 2026
pulisher
Oct 19, 2026

Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up? - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

Johnson & Johnson Reports 48-Week Tremfya Results in Phase 3 Crohn’s Disease Fistula Study - Yahoo

Oct 19, 2026
pulisher
Oct 19, 2026

3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool

Oct 19, 2026
pulisher
Oct 19, 2026

Stryker Enters Soft-Tissue Robotics With $400 Million CMR Deal - Zacks Investment Research

Oct 19, 2026
pulisher
Oct 19, 2026

Has Johnson & Johnson Stock Become A Different Bet? - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

Johnson & Johnson (JNJ) Has Improved, but I’m Holding Off after the Rally - TipRanks

Oct 19, 2026
pulisher
Oct 19, 2026

AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research

Oct 19, 2026
pulisher
Oct 19, 2026

Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - Yahoo Finance

Oct 19, 2026
pulisher
Oct 19, 2026

Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead - AOL.com

Oct 19, 2026
pulisher
Oct 19, 2026

Zacks Investment Ideas feature highlights: Intuitive Surgical - Zacks Investment Research

Oct 19, 2026
pulisher
Oct 19, 2026

Johnson & Johnson (NYSE:JNJ): Can Drug Advances Strengthen the S&P 500? - Kalkine Media

Oct 19, 2026
pulisher
Oct 19, 2026

What Does Johnson & Johnson (JNJ) News Mean For Its Growth Case? - Simply Wall Street

Oct 19, 2026
pulisher
Oct 17, 2026

JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law - The National Law Review

Oct 17, 2026
pulisher
Oct 17, 2026

Should You Invest in This Dividend King on the Dip? - The Motley Fool

Oct 17, 2026
pulisher
Oct 17, 2026

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool

Oct 17, 2026
pulisher
Oct 17, 2026

Johnson & Johnson Just Raised Its Sales Outlook Again. Here's Why the Dividend King Is Still a Buy. - The Motley Fool

Oct 17, 2026
pulisher
Oct 17, 2026

Former J&J site cleared for £31m redevelopment - BBC

Oct 17, 2026
pulisher
Oct 16, 2026

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 16, 2026
pulisher
Oct 16, 2026

Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside - Zacks Investment Research

Oct 16, 2026
pulisher
Oct 16, 2026

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Oct 16, 2026
pulisher
Oct 16, 2026

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - Yahoo Finance

Oct 16, 2026
pulisher
Oct 16, 2026

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Oct 16, 2026
pulisher
Oct 16, 2026

This Unstoppable Vanguard ETF Could Turn $500 Per Month Into $1 Million Over the Long Term - The Motley Fool

Oct 16, 2026
pulisher
Oct 16, 2026

Dividend Roundup: Johnson & Johnson, Coca-Cola, Costco, CVS Health, and more - Seeking Alpha

Oct 16, 2026
pulisher
Oct 16, 2026

Breakfast News: Week in Review - The Motley Fool

Oct 16, 2026
pulisher
Oct 15, 2026

Breaking Down The Big 3 Investing Strategies - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

3 Companies Raising Guidance This Earnings Season - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive? - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Johnson & Johnson reports mixed Q3 earnings - Healthcare Brew

Oct 15, 2026
pulisher
Oct 15, 2026

Where Could Johnson & Johnson’s Next Growth Come From? - Trefis

Oct 15, 2026
pulisher
Oct 15, 2026

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 14, 2026

Johnson & Johnson CFO taps internal investment for medtech growth - CFO Dive

Oct 14, 2026
pulisher
Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView

Oct 14, 2026

Johnson Johnson (JNJ) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Johnson Johnson (JNJ) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Schmid Timothy
EVP, WW Chair, MedTech
Sep 02 '26
Sale
274.74
33,597
9,230,440
25,447
Schmid Timothy
Officer
Sep 02 '26
Proposed Sale
274.74
33,597
9,230,440
0
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Aug 17 '26
Sale
263.36
15,000
3,950,400
194,451
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Aug 17 '26
Option Exercise
115.67
15,000
1,735,050
209,451
Taubert Jennifer L
Officer
Aug 17 '26
Proposed Sale
263.36
15,000
3,950,418
0
Duato Joaquin
CEO and Chairman of the Board
Aug 13 '26
Option Exercise
115.67
123,291
14,261,070
399,258
Duato Joaquin
CEO and Chairman of the Board
Aug 13 '26
Sale
261.17
123,291
32,199,927
275,967
Duato Joaquin
Officer
Aug 13 '26
Proposed Sale
261.17
123,291
32,199,927
0
Forminard Elizabeth
EVP, Chief Legal Officer
Aug 06 '26
Option Exercise
131.94
9,344
1,232,847
32,912
Forminard Elizabeth
EVP, Chief Legal Officer
Aug 06 '26
Sale
257.00
15,918
4,090,960
16,994
$284.80
price down icon 1.48%
MRK MRK
$149.88
price up icon 1.07%
NVS NVS
$153.93
price up icon 0.19%
AZN AZN
$168.45
price down icon 0.22%
$438.34
price down icon 0.14%
$153.57
price down icon 1.88%
大文字化:     |  ボリューム (24 時間):